International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025
Introduction of DNA-HPV test in the Brazilian cervical cancer screening program: When the idea is good but does not fit the budget.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Urbano Felipe Polido, Cury Gabriel Russo, Dos Santos Caio Rodrigo, da Silva Daniel José Castilho, Xavier-Júnior José Cândido Caldeira
Аннотация
OBJECTIVE: To evaluate the financial applicability of the DNA-HPV test for cervical cancer screening in a developing country like Brazil.
METHODS: This was a retrospective, observational study based on documentary data, conducted to assess the cost-effectiveness of cervical cancer screening strategies in Brazil. The study used national cervical cancer screening data collected between January 1 and December 31, 2020 for women between 25 and 64 years old, performing a cost-effectiveness assessment of two different screening tests. No sensitivity analysis was conducted due to the descriptive nature of this preliminary cost assessment.
RESULTS: Based on the cervical smear, the Brazilian protocol has an estimated cost of US$117.5 million. In contrast, when using the HPV DNA test, the estimated cost is US$1.39 billion.
CONCLUSION: The current use of the cervical smear is the least expensive and the only one that aligns with Brazil's financial resources allocated to health.
METHODS: This was a retrospective, observational study based on documentary data, conducted to assess the cost-effectiveness of cervical cancer screening strategies in Brazil. The study used national cervical cancer screening data collected between January 1 and December 31, 2020 for women between 25 and 64 years old, performing a cost-effectiveness assessment of two different screening tests. No sensitivity analysis was conducted due to the descriptive nature of this preliminary cost assessment.
RESULTS: Based on the cervical smear, the Brazilian protocol has an estimated cost of US$117.5 million. In contrast, when using the HPV DNA test, the estimated cost is US$1.39 billion.
CONCLUSION: The current use of the cervical smear is the least expensive and the only one that aligns with Brazil's financial resources allocated to health.